Strata Beats, Hits Its 2027 Margin Goal Two Years Early — Then Tells You Q4 Looks Flat

A record cash quarter and a first-ever buyback, set against the uncomfortable fact that the company's own bull thesis — continuous distribution — just showed its downside in lungs.

SRTA · Earnings Call · 2026-11-03

The beat is real; the setup is not the one management wanted

Strata Critical Medical reported fiscal Q3 2026 on November 3 with revenue up 50.3% to $74.1 million (8.5% on a pro forma basis), gross margin of 22.7%, adjusted EBITDA of $9.6 million at a 13% margin, and a record $8.6 million of free cash flow. Those numbers sit on top of a filed base that was still mediocre: the June quarter, the last one in the SEC record, showed revenue of $73 million and a 21.0% gross margin. Free cash flow had only just crossed toward breakeven at negative half a million dollars. So the quarter genuinely is an inflection, not a re-labeling. But the guidance was not. Management reiterated 2026 revenue of $285–295 million and adjusted EBITDA of $33–35 million, and Will Heyburn conceded something the market will not enjoy: “we have not yet seen the typical seasonal sequential improvement in industry volumes or in our own logistics volume so far in Q4” — William Heyburn, President and COO · 2026-11-03. Transplant volumes in October were down low-single-digits industry-wide. That is the tension running through this whole call: better margins, better cash, worse volumes.

The margin win is a shrink-to-grow story

The headline operational fact is that the clinical segment carried the quarter — revenue up 20.3% sequentially, with Heyburn claiming like-for-like growth of “30% plus” — William Heyburn, President and COO · 2026-11-03 year over year — while logistics shrank 6.9% sequentially. And yet logistics gross margin rebounded 240 basis points to 20.8%, which Heyburn described as “well ahead of our goal to reach 20% in 2027” — William Heyburn, President and COO · 2026-11-03. A 2027 target delivered in 2026. The credit belongs to a plan laid out two quarters ago, when Heyburn told analysts the company had “proactively removed 1 or 2 of our lowest margin airplanes from the overall addressable fleet” — William Heyburn, President or Head of Clinical Services · 2026-08-04. That is now visible in the numbers. But note the shape of the win: margin up while revenue falls, because trip distance fell roughly 10% industry-wide year over year and fuel surcharge pass-through revenue inflated the top line at lower margin. This is a business being optimized into a smaller, better version of itself while the growth migrates to integrated transplant offering cases worth up to 3x a transport-only case. That is strategically coherent. It also means logistics — the historic core — is now the drag, and management is explicit that 2027 growth will be led by Clinical while logistics slows. The share gains argument rests on the local recovery model, which uses locally based surgeons and commercial flights to cut dry run costs on the ~30% of DCD cases that never produce a usable organ.

Continuous distribution cuts both ways — and lungs just proved it

The most honest thing on this call is also the most uncomfortable. Strata's top two keywords this quarter are continuous distribution and trip distance — the same policy framework that has been the company's structural bull case for years. In May, CFO Mat Schneider told analysts that over five years there had been “about a 60% increase in the distance organs are traveling” — Mathew Schneider, Chief Financial Officer · 2026-05-06, driven by regulatory change. On the same call, when Bill Bonello flagged a modest reduction in average transport distance, Schneider pushed back: “quite the opposite in terms of our view” — Mathew Schneider, Chief Financial Officer · 2026-05-06. Two quarters later, the opposite happened. An OPTN change in May to the lung composite allocation score re-weighted distance back into the formula, and lung trip distances fell roughly 20% year over year in Q3, with lung at about 20% of Strata's mix. Melissa Tomkiel was careful to frame it as “a tweak to the weighting” — Melissa Tomkiel, CEO · 2026-11-03, noting distances remain up about 80% from the original adoption of continuous allocation for lungs. Fair. But the mechanism is now demonstrated: the same policy lever that lengthens trips can shorten them.

Bill, it's really hard to draw a conclusion in just 1 quarter... if this was the new normal, you're talking about a low single-digit headwind.
William Heyburn, President and COO · 2026-11-03

Heart and liver — more than half of transport volumes — have yet to move to continuous distribution, and management still expects that to be a net positive on both volume and distance. But after this quarter, that thesis is a hope with a precedent against it, not a one-way trade.

The buyback is the real tell

Strata authorized a $20 million share repurchase — roughly 5% of a $393 million market cap priced at 1.8x revenue. That is a genuine capital-allocation pivot for a company whose entire public narrative for six quarters has been bolt-on acquisitions at mid-single-digit EBITDA multiples. Heyburn's framing was unusually blunt: “this is good corporate finance, good opportunity to return some cash to shareholders rather than just having it sit on the balance sheet” — William Heyburn, President and COO · 2026-11-03. The stock is down 14.3% over 90 days and 28.8% from its August 21 high of $6.24, so the attractive valuation claim is not self-serving fantasy. And the balance sheet supports it: $41.6 million of cash plus $27.5 million of earnout consideration expected in Q1 2027, with the Joby earnout already delivering $15.3 million net this quarter. Two caveats worth flagging. First, the $8.6 million of free cash flow “benefited from a low level of aircraft capitalized maintenance resulting in only $0.8 million of capital expenditures in the quarter” — William Heyburn, President and COO · 2026-11-03 — a maintenance-light quarter, not a structural capex reset. Second, stock based compensation expense hit $5 million, inflated by performance units tied to that earnout, which is why GAAP showed a $7.6 million loss. Management guides SBC down 20–30% into Q4.

What is genuinely new

Beyond the buyback, Strata launched a cardiothoracic surgical locum tenens business in October with its first customer — lending its surgeons to hospitals for non-transplant cases. Tomkiel called it “a huge new addressable market for us” — Melissa Tomkiel, CEO · 2026-11-03. It appears in no prior keyword set, and its logic is double-sided: new revenue, plus higher surgeon utilization and retention, feeding the attractive employer problem that constrains local recovery capacity. Notably absent this quarter: any fresh talk of acquisition targets or pipeline specifics beyond "well ahead of plan" — over $6 million of annualized adjusted EBITDA closed at target multiples. The M&A narrative has shifted from what to how fast, and the buyback is the residual claim on that. The watch item into 2027 is whether the clinical mix shift converts into the cash conversion management promises, or whether the 59.9% receivables-to-revenue ratio keeps absorbing it. For a $393 million company that just found its margin target early, the next two quarters of volume data matter more than the buyback.